Drug
Ak101
Ak101: highest development phase Phase 3, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK101 NCT05120297 | Phase 3 | Psoriasis Vulgaris |
Latest
No recent events.
Follow Ak101 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.